Table 3 Treat-related adverse events (n = 52)
TRAEs | All grades | Grade 1–2 | Grade 3 or more |
|---|---|---|---|
Neutropenia | 29 (55.8%) | 7 (13.5%) | 22 (42.3%) |
Leukopenia | 30 (57.7%) | 13 (25.0%) | 17 (32.7%) |
Febrile neutropenia | 6 (11.5%) | 0 | 6 (11.5%) |
Thrombocytopenia | 11 (21.2%) | 10 (19.2%) | 1 (1.9%) |
Anemia | 41 (78.8%) | 41 (78.8%) | 0 |
Nausea | 19 (36.5%) | 15 (28.8%) | 4 (7.7%) |
Fatigue | 13 (25.0%) | 10 (19.2%) | 3 (5.8%) |
Infection | 4 (7.7%) | 1 (1.9%) | 3 (5.8%) |
Anorexia | 6 (11.5%) | 5 (9.6%) | 1 (1.9%) |
Oral ulcers | 3 (5.8%) | 2 (3.8%) | 1 (1.9%) |
Hypertriglyceridemia | 20 (38.5%) | 20 (38.5%) | 0 |
Hypercholesterolemia | 20 (38.5%) | 20 (38.5%) | 0 |
Hyperglycemia | 14 (26.9%) | 14 (26.9%) | 0 |
Limb numbness | 14 (26.9%) | 14 (26.9%) | 0 |
Creatinine elevated | 11 (21.2%) | 11 (21.2%) | 0 |
Rash | 11 (21.2%) | 11 (21.2%) | 0 |
ALT elevated | 10 (19.2%) | 10 (19.2%) | 0 |
Diarrhea | 8 (15.4%) | 8 (15.4%) | 0 |
Hypertension | 6 (11.5%) | 6 (11.5%) | 0 |
AST elevated | 6 (11.5%) | 6 (11.5%) | 0 |
Edema | 4 (7.7%) | 4 (7.7%) | 0 |
Alopecia | 3 (5.8%) | 3 (5.8%) | 0 |
Otitis | 2 (3.8%) | 2 (3.8%) | 0 |
Hyperkalemia | 2 (3.8%) | 2 (3.8%) | 0 |
Pigmentation | 1 (1.9%) | 1 (1.9%) | 0 |
Dyspnea | 1 (1.9%) | 1 (1.9%) | 0 |